Washington, United States: The US Food and Drug Administration's approval process for a controversial drug used to treat Alzheimer's was "rife with irregularities," a congressional report said Thursday (Friday in Manila).
An 18-month investigation into the FDA's green-lighting of the drug, Aduhelm, also criticized its manufacturer, biotechnology company Biogen.
Already have an active account? Log in here.
Continue reading with one of these options:
Continue reading with one of these options:
Premium + Digital Edition
Ad-free access
P 80 per month
(billed annually at P 960)
- Unlimited ad-free access to website articles
- Limited offer: Subscribe today and get digital edition access for free (accessible with up to 3 devices)
TRY FREE FOR 14 DAYS
See details
See details
If you have an active account, log in
here
.